---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-25-000033"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:07:00.025868+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PacBio Q4 rev $39.2M (-33% YoY), $90M impairment, non-GAAP loss $55.3M

## Summary
- Revenue $39.2M vs $58.4M prior year; instrument revenue fell to $15.3M from $35.1M.
- GAAP net income of $3.6M includes $154.4M gain on debt restructuring; non-GAAP net loss $55.3M ($0.20 loss per share).
- Preliminary non-cash impairment charges of ~$90.1M for goodwill and IPR&D due to macroeconomic headwinds.
- Cash $389.9M, down from $631.4M; convertible note exchange reduced principal by $259M.
- Launched Vega benchtop platform and SPRQ chemistry enabling sub-$500 genome, with 23 Revio and 7 Vega systems shipped.

## SEC filing metadata
- accession: 0001299130-25-000033
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000033/0001299130-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000033/pacb-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-25-000033
- JSON: https://secwatch.observer/filing/0001299130-25-000033.json
- Plain text: https://secwatch.observer/filing/0001299130-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.